ArticleClinical epidemiology2022
Temporal Trends and Projections of Bladder Cancer Burden in China from 1990 to 2030: Findings from the Global Burden of Disease Study.
Article in Clinical epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.Cancer medicine · 2024Trial
- Development and initial psychometric evaluation of a discharge readiness scale in patients undergoing orthotopic neobladder reconstruction after radical cystectomy.International journal of nursing studies advances · 2026Article
- Hemostatic Efficacy and Clinical Outcomes of Radiotherapy in Older Adult Patients With Advanced Bladder Cancer and Hematuria Unsuitable for Standard Treatment.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Knowledge, attitudes, and practices related to health management among patients receiving intravesical instillation.Frontiers in oncology · 2026Article
- Global, regional, and national burden of bladder cancer from 1990 to 2021 with projections to 2050: insights from the global burden of disease study and Mendelian randomization analysis.Infectious agents and cancer · 2025Article
- Sex-Specific Associations of Glycemic Status and Smoking with Bladder Cancer Risk: A Nationwide Cohort Study.Cancers · 2025Article
- Disease burden of bladder cancer in China and the different SDI regions over the world from 1990 to 2021.Scientific reports · 2025Article
- Analysis of long-term trends and 15-year predictions of smoking-related bladder cancer burden in china across different age and sex groups from 1990 to 2021.Discover oncology · 2025Article
- Explainable machine learning to predict postoperative ileus after radical cystectomy: an 11-year real-world cohort.Frontiers in artificial intelligence · 2025Article
- Integrating single cell and bulk RNA sequencing data identifies RBM17 as a novel response biomarker for immunotherapy in bladder cancer.Virchows Archiv : an international journal of pathology · 2024Article
- BLCA prognostic model creation and validation based on immune gene-metabolic gene combination.Discover oncology · 2023Article
- Observational
- Current status and temporal trend in incidence, death, and burden of esophageal cancer from 1990-2019.Thoracic cancer · 2023Article
- Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma.Frontiers in oncology · 2023Article
- Weakly supervised deep learning for multimodal MRI-TRUS registration: Toward assisting prostate biopsy guidance.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Identifying disease burden and risk factors of bladder cancer and projecting its epidemiological trend in China, which can provide reference data to formulate measures for its management and prevention. Methods: We analyzed the incidence, mortality, and disability-adjusted life-years (DALYs) data of bladder cancer in China from 1990 to 2019 and predicted to 2030 based on the Global Burden of Disease Study 2019. We also estimated the proportion of risk factors contributing to bladder cancer DALYs. The average annual percentage change (AAPC) in both sexes was calculated to quantify the temporal trends. Results: In China, the age-standardized incidence rate of bladder cancer increased from 3.3/100,000 in 1990 to 5.16/100,000 in 2019 (AAPC of 1.47), while the age-standardized mortality rate and age-standardized DALYs rate declined slightly (AAPC of -0.58 and -0.65, respectively). The burden of bladder cancer increased with age, which reached a peak over 85 years old. The main risk factor for bladder cancer was smoking, and the contribution of high fasting plasma glucose increased from 1990 to 2019, with an AAPC of 0.85 in males and 0.61 in females. We predicted total incident cases, deaths and DALYs will increase to 150,372 and 53,520 and 1043,688 in 2030, respectively. The disease burden of bladder cancer in males will consistently higher than that in females from 2020 to 2030. Conclusion: Although mortality and DALYs rates showed downward trends, the disease burden remained heavy in China at present. More effective and long-term health policies are needed to develop for early prevention and treatment of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.